Patent Suits Trigger Molecular Diagnostics Business Uncertainty
This article was originally published in The Gray Sheet
Executive Summary
Investment in new molecular diagnostics biomarkers, particularly genetic markers, is suffering due to substantial patent law uncertainties, according to test developers at last week's Biotechnology Industry Organization conference in Chicago
You may also be interested in...
Supreme Court To Hear Prometheus Diagnostics Patent Case
The Supreme Court will take another stab at mapping out a border between patentable and unpatentable diagnostic method claims.
Supreme Court To Hear Prometheus Diagnostics Patent Case
The Supreme Court will take another stab at mapping out a border between patentable and unpatentable diagnostic method claims.
Myriad's BRCA Gene Patents Struck Down In Court; Firm Downplays Impact
A federal court ruling invalidating Myriad Genetics' BRCA1 and BRCA2 cancer gene patents will have limited immediate impact on the biotech/diagnostics industry